Celgene Corporation

Other

Louisiana State University and Agricultural & Mechanical College

Theravasc Inc.

Signal Pharmaceuticals, Inc.

Kyle Chan

Robert J Hariri

David I Stirling

Christopher Kevil

Helen A Brady

Amol Soin

Gregory D Ferguson

Normand R Richard

Anthony J Giordano

Dominique Verhelle

Anthony Giordano

Laure Moutouh-De Parseval

Helen Brady

The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO). The pharmaceutical compositions of the invention are useful, for example, for treating or reducing pain, improving symptoms of a microvascular disease, and improving nerve conduction velocity.

Pharmaceutical formulations of nitrite and uses thereof

The present invention relates to pharmaceutical compositions of nitrites such as inorganic nitrites, or any pharmaceutically acceptable salts, solvates, or prodrugs thereof, and the medical use of these compositions. The pharmaceutical compositions, which can be formulated for oral administration, can provide immediate release or extended release of the nitrite ion (NO). The pharmaceutical compositions of the invention are useful, for example, for modulating brain function, in particular improving mood and/or psychological state, in the treatment of disorders of brain development, and in the treatment and/or reduction of pain.

Provided herein are methods of treating, preventing or managing disorders associated with low CD59 levels. The methods encompass the administration of an immunomodulatory compound provided herein, such as 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione or 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline. Further described are methods of treatment using the immunomodulatory compounds in combination with other therapeutic agents or therapies. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods provided herein are also disclosed.

Methods using immunomodulatory compounds for modulating level of CD59

Methods of determining the activity of an immunomodulatory compound by measuring the presence of an miRNA in a sample are disclosed. Additionally disclosed are methods of assessing the patient compliance in patients treated with an immunomodulatory compound.

Use of micro-RNA as a biomarker of immunomodulatory drug activity

Growing community of inventors

San Diego, CA, United States of America

Kyle Chan